Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3508737 | 0.99 | F10 (0.46) | F10F2GAADGAT2 | |
| SCHEMBL8225098 | 0.91 | F10 (0.50) | F10F2GAA | |
| SCHEMBL3507150 | 0.91 | F10 (0.49) | F10F2 | |
| SCHEMBL8225130 | 0.89 | F10 (0.59) | F10F2 | |
| Hydrochloric Acid SCHEMBL3507990 | 0.88 | F10 (0.58) | F10F2 | |
| SCHEMBL13271874 | 0.81 | F10 (0.48) | F10F2 | |
| SCHEMBL3510008 | 0.79 | F10 (0.65) | F10F2 | |
| SCHEMBL8230562 | 0.79 | F10 (0.60) | F10F2 | |
| SCHEMBL3246184 | 0.78 | F10 (0.38) | F10F2DGAT2 | |
| Hydrochloric Acid SCHEMBL3506415 | 0.78 | F10 (0.59) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263624-B2 | Aryl-substituted heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263624-B2 | Aryl-substituted heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20100029651-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | BAYER HEALTHCARE AG | 2010-02-04 | — | — | US | disclosed |
| US-20100029651-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | BAYER HEALTHCARE AG | 2010-02-04 | — | — | US | disclosed |
| WO-2007137791-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029651-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | AHR, CYP2C19, PAH | F10 229/4885F2 30/4885GAA 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.